Decker Wealth Management LLC Invests $1.52 Million in Abbott Laboratories $ABT

Key Points

• Decker Wealth Management opened a new position in Abbott Laboratories, buying 14,786 shares worth about $1.52 million in the first quarter.
• Abbott’s latest quarterly results came in ahead of expectations, with EPS of $1.31 versus estimates of $1.28, and the company raised its 2026 full-year EPS guidance to $5.45-$5.60.
• Insider buying and analyst sentiment both appeared constructive: director Daniel J. Starks and CFO Philip P. Boudreau made purchases, while analysts maintained a Moderate Buy consensus with an average price target of $118.61.

Decker Wealth Management LLC bought a new stake in Abbott Laboratories (NYSE:ABT - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 14,786 shares of the healthcare product maker's stock, valued at approximately $1,518,000.

Several other large investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in shares of Abbott Laboratories by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker's stock valued at $21,995,501,000 after acquiring an additional 2,402,408 shares during the last quarter. State Street Corp grew its holdings in Abbott Laboratories by 2.1% in the fourth quarter. State Street Corp now owns 79,853,782 shares of the healthcare product maker's stock valued at $10,004,880,000 after purchasing an additional 1,627,791 shares during the period. Capital International Investors increased its position in Abbott Laboratories by 2.6% during the fourth quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker's stock worth $7,922,519,000 after purchasing an additional 1,614,706 shares during the last quarter. J. Stern & Co. LLP increased its position in Abbott Laboratories by 12,439.6% during the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker's stock worth $4,926,279,000 after purchasing an additional 39,005,451 shares during the last quarter. Finally, Capital Research Global Investors raised its stake in Abbott Laboratories by 1.0% during the fourth quarter. Capital Research Global Investors now owns 39,169,239 shares of the healthcare product maker's stock worth $4,907,523,000 after purchasing an additional 400,400 shares during the period. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Daniel J. Starks acquired 10,000 shares of the stock in a transaction on Monday, April 27th. The stock was bought at an average price of $92.65 per share, with a total value of $926,500.00. Following the completion of the transaction, the director directly owned 6,751,103 shares of the company's stock, valued at $625,489,692.95. The trade was a 0.15% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Philip P. Boudreau acquired 2,200 shares of the company's stock in a transaction dated Thursday, April 23rd. The shares were purchased at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the purchase, the chief financial officer directly owned 2,200 shares of the company's stock, valued at approximately $201,300. This trade represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 0.46% of the company's stock.

Analyst Ratings Changes

Several analysts have recently issued reports on ABT shares. BTIG Research boosted their price objective on shares of Abbott Laboratories from $131.00 to $134.00 and gave the company a "buy" rating in a research note on Friday. Mizuho cut their target price on Abbott Laboratories from $125.00 to $115.00 and set a "neutral" rating on the stock in a research report on Friday, April 17th. Oppenheimer reduced their target price on Abbott Laboratories from $132.00 to $115.00 and set an "outperform" rating on the stock in a report on Friday, April 17th. Bank of America dropped their price target on Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. Finally, Barclays cut their price objective on Abbott Laboratories from $144.00 to $143.00 and set an "overweight" rating on the stock in a report on Monday, April 20th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $118.61.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $100.71 on Monday. The company's fifty day simple moving average is $89.89 and its 200-day simple moving average is $102.01. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The company has a market cap of $175.41 billion, a PE ratio of 32.59, a P/E/G ratio of 1.73 and a beta of 0.61.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping analysts' consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.65%. The firm had revenue of $12.51 billion during the quarter, compared to analysts' expectations of $12.52 billion. During the same period in the prior year, the company earned $1.26 EPS. The firm's revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities research analysts anticipate that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be given a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.5%. Abbott Laboratories's dividend payout ratio is presently 81.55%.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott beat Q2 earnings expectations and raised 2026 adjusted EPS guidance to $5.45-$5.60, signaling better profit momentum for the rest of the year. Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
• Positive Sentiment: Management pointed to stronger second-half demand across multiple businesses, including nutrition, medical devices, diagnostics, and diabetes care, which supports a faster growth profile. ABT Q2 Earnings Call Flags Stronger Second-Half Setup
• Positive Sentiment: Analysts turned more constructive after the results, with JPMorgan, Citi, Piper Sandler, Wells Fargo, TD Cowen, BTIG, and RBC all lifting targets or reaffirming bullish views. These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.